114 related articles for article (PubMed ID: 32163373)
1. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
He L; Chen C; Gao G; Xu K; Ma Z
Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
[TBL] [Abstract][Full Text] [Related]
2. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
Yang L; Jing Y; Xia X; Yin X
J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
[TBL] [Abstract][Full Text] [Related]
3. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.
Saraswat A; Vemana HP; Dukhande VV; Patel K
Heliyon; 2022 Jan; 8(1):e08702. PubMed ID: 35036599
[TBL] [Abstract][Full Text] [Related]
4. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
Saraswat A; Vartak R; Hegazy R; Fu Y; Rao TJR; Billack B; Patel K
Biomed Pharmacother; 2023 Dec; 168():115754. PubMed ID: 37871557
[TBL] [Abstract][Full Text] [Related]
5. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
[TBL] [Abstract][Full Text] [Related]
6. A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer.
Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
[TBL] [Abstract][Full Text] [Related]
7. BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10.
Ma Y; Liu N; Shi Y; Ma S; Wang Y; Zheng W; Sun R; Song Y; Chen M; Qu L; Mao R; Fan Y
Cell Signal; 2024 Jul; 119():111173. PubMed ID: 38604343
[TBL] [Abstract][Full Text] [Related]
8. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both
Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
[TBL] [Abstract][Full Text] [Related]
9. Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.
Bond AG; Craigon C; Chan KH; Testa A; Karapetsas A; Fasimoye R; Macartney T; Blow JJ; Alessi DR; Ciulli A
J Med Chem; 2021 Oct; 64(20):15477-15502. PubMed ID: 34652918
[TBL] [Abstract][Full Text] [Related]
10. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
11. Sanguinarine targets BRD4 to suppress cell proliferation and migration in clear cell renal cell carcinoma.
Wen Y; Song Y; Ma Y; Wen J; Yang J
J Biochem Mol Toxicol; 2023 Nov; 37(11):e23451. PubMed ID: 37393519
[TBL] [Abstract][Full Text] [Related]
12. A BRD4-Targeting Photothermal Agent for Controlled Protein Degradation.
Shi M; Li Y; Pan W; Fu Z; Wang K; Liu X; Li N; Tang B
Angew Chem Int Ed Engl; 2024 May; ():e202403258. PubMed ID: 38721770
[TBL] [Abstract][Full Text] [Related]
13.
Liu H; Xiong H; Li C; Xu M; Yun Y; Ruan Y; Tang L; Zhang T; Su D; Sun X
Small; 2024 Apr; ():e2310865. PubMed ID: 38678537
[TBL] [Abstract][Full Text] [Related]
14. I-BET726 suppresses human skin squamous cell carcinoma cell growth in vitro and in vivo.
Liu Z; Li P; Yang YQ; Cai S; Lin X; Chen MB; Guo H
Cell Death Dis; 2020 May; 11(5):318. PubMed ID: 32371868
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells.
Qin AC; Jin H; Song Y; Gao Y; Chen YF; Zhou LN; Wang SS; Lu XS
Cell Death Dis; 2020 Sep; 11(9):805. PubMed ID: 32978368
[TBL] [Abstract][Full Text] [Related]
16. Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy.
Nguyen KM; Busino L
Semin Cancer Biol; 2020 Dec; 67(Pt 2):53-60. PubMed ID: 32200025
[TBL] [Abstract][Full Text] [Related]
17. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
18. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
19. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
